Methanol Poisoning: Factors Associated with Neurologic Complications

Todd J. Anderson, Ashfaq Shuaib and Werner J. Becker

ABSTRACT: Hospital records of thirty patients with methanol poisoning were studied. Neurologic manifestations at presentation including coma, seizures and decreased visual acuity were seen in nineteen patients. The mean blood pH at presentation was significantly lower in the patients with these neurologic signs and symptoms than in the eleven patients without them (p < 0.05). Methanol levels at presentation tended to be higher in patients with neurologic manifestations at presentation and these patients tended to present later after methanol ingestion than those patients without neurologic manifestations. Fifteen patients with methanol poisoning developed serious neurologic sequelae or died. The mean blood pH was significantly lower in this patient group than in those who survived without neurologic sequelae (p < 0.05). Methanol levels at presentation were not different in the patients who developed neurologic sequelae or died as compared to those who did not. The time from ingestion of methanol to presentation at the hospital was however significantly longer in those patients who developed neurologic sequelae or died (p < 0.05). Initiation of treatment within eight hours of ingestion of methanol was associated with a better clinical outcome.


Methanol ingestion can result in serious toxicity, and many cases have been reported in the medical literature. The ingested methanol is converted to formic acid, the toxic metabolite responsible for many of the clinical manifestations and also for the high anion gap metabolic acidosis that accompanies methanol toxicity. Symptoms resulting from methanol poisoning include visual disturbances ranging from blurred vision to blindness, altered consciousness, nausea, vomiting, abdominal pain, headache and dyspnea. The physical signs of methanol poisoning are not specific, but include non-reactive pupils, retinal edema, hyperaemia of the optic disc, disorientation, decreased level of consciousness and abdominal tenderness.

Standard treatment consists of intravenous bicarbonate for the acidosis, administration of ethanol to inhibit conversion of methanol to formate, and hemodialysis to remove methanol and formate. Recovery from methanol poisoning is often complete, but serious complications including ocular toxicity and neurologic sequelae can occur.

There is little information available in the literature to explain why some patients present with neurologic symptoms and signs, and why some patients but not others go on to develop major neurologic sequelae. To answer these questions, we have reviewed our experience with methanol poisoning over the last ten years with regard to the neurologic manifestations of methanol ingestion.

From the Departments of Internal Medicine, and Clinical Neurosciences, University of Calgary, Calgary

Received June 7, 1988. Accepted in final form June 19, 1989

Reprint requests to: Dr. Werner J. Becker, Calgary General Hospital, M4-022, 841 Centre Ave. E., Calgary, Alberta, Canada T2E 0A1
METHODS

Hospital charts of patients admitted with a diagnosis of methanol poisoning over the past ten years to hospitals affiliated with the University of Calgary were reviewed retrospectively. Patients were included in the study if an anion gap of greater than 20 was present with no underlying cause other than methanol ingestion, and if methanol was detected in the serum. Using these criteria, 30 patients were admitted to the study. Patients were treated in an intensive care unit with intravenous bicarbonate, intravenous ethanol and hemodialysis until methanol was no longer detectable in the serum. Treatment was always begun within one hour of presentation.

We reviewed the patient records for neurologic manifestations at clinical presentation and for evidence of long term neurologic sequelae. Patients were considered to have neurologic signs and symptoms at presentation if they had seizures, coma, or decreased visual acuity (20/100 or worse) on admission. Visual acuity had been measured in all patients who complained of visual symptoms. Neurologic sequelae were considered to be present if patients showed a persistent reduction in visual acuity to less than 20/100, or showed persistent major abnormalities in the neurologic examination. Patient follow-up was limited to the length of their hospital stay for most patients. Follow-up for patients with reduced visual acuity was 4 to 30 days, and for the patients with more major neurologic sequelae ranged from several months to over one year. Final patient outcome with regard to survival or death was also recorded. Although the immediate cause of death is not always known in patients dying of methanol toxicity, many groups have demonstrated at autopsy sufficient damage to the brain to account for death.

Patients who survived without neurologic sequelae recovered completely.

Student’s T test (unpaired) was used to compare the groups in Tables 2 and 3. The values expressed are means +/- one standard deviation. A Chi squared analysis with Yates correction was used in Table 4.

RESULTS

The thirty patients studied included twelve females and eighteen males. Patient mean age was 29.4 years (range 14-55). The symptoms and signs at presentation are listed in Table 1. Nineteen patients presented with neurologic manifestations. Ten patients presented with coma, three with seizures, three with coma and seizures, and three with reduced visual acuity. Of the thirteen who were comatose on arrival at the hospital, seven died. The three patients with reduced visual acuity at presentation were all left with visual sequelae. Four of the six patients presenting with seizures died, one was left with a persistent seizure disorder, and only one of the six patients made a full recovery.

The mean blood pH was significantly lower in the patients with neurologic manifestations on admission (Table 2). Although the methanol levels tended to be higher in patients with neurologic symptoms and signs than in those without neurologic manifestations, there was considerable overlap between the two groups. Most of the patients with initial neurologic manifestations arrived at hospital more than eight hours after methanol ingestion. However the time from ingestion to presentation was not significantly different in the patients with neurologic manifestations as compared to those without (Table 4).

Neurologic Sequelae

Fifteen of the thirty patients went on to develop long term neurologic sequelae or died. These included four patients with ocular toxicity defined as a decrease in visual acuity to less than 20/100. Three other patients developed neurologic sequelae secondary to central nervous system damage. These patients have been reported previously. One, a 55 year old female, remained in a chronic vegetative state. Her CT scan showed diffuse white and grey matter destruction. Another patient, a 31-year-old male, developed a transverse myelopathy at T4. The third patient, a 30-year-old male, showed persistent personality and cognitive changes. Eight patients died. The mean blood pH was significantly decreased in this group of fifteen patients with poor neurologic outcome or death as compared to the mean blood pH in the fifteen patients with good outcome (Table 3). Clinical outcome was also improved if treatment was initiated within eight hours of methanol ingestion. None of the five patients in whom treatment was started within eight hours of ingestion developed neurologic sequelae or died (Table 4). Methanol levels were not different in patients with neurologic sequelae or death as compared to patients with good outcome.

DISCUSSION

Methanol poisoning has long been associated with a high mortality rate. The mortality rate of 26% in our patient series is comparable to previous reports. Survivors of methanol poisoning may be left with serious long term neurologic sequelae.

Table 2: Methanol Levels and pH at Presentation as Related to the Presence of Major Neurologic Symptoms and Signs at Presentation

<table>
<thead>
<tr>
<th>Variable</th>
<th>Major Neurologic Symptoms and Signs (n=19)</th>
<th>No Major Neurologic Symptoms and Signs (n=11)</th>
</tr>
</thead>
<tbody>
<tr>
<td>MEAN pH</td>
<td>6.96 +/- 0.28 (range 6.46 - 7.42)</td>
<td>7.24 +/- 10.07 (range 7.16 - 7.35)</td>
</tr>
<tr>
<td>MEAN METHANOL</td>
<td>93.8 +/- 90 (range 4 - 213)</td>
<td>34 +/- 26 (range 1 - 315)</td>
</tr>
</tbody>
</table>

*p < 0.05
NS Not significant
These are being recognized with increasing frequency as more patients survive because of intensive care unit treatment. Visual sequelae with optic disc pallor, retinal edema and blindness have been reported. Sharpe et al have described optic nerve demyelination with relative preservation of axons in patients dying of methanol poisoning. White matter destruction elsewhere in the central nervous system has also been seen. Putaminal hemorrhage on CT scan has been reported after methanol poisoning and was noted on CT scan in two of our patients with neurologic sequelae. Autopsy studies on patients with methanol poisoning have shown changes ranging from mild cerebral edema to large basal ganglia hemorrhages. Basal ganglia hemorrhage is a common finding in patients dying of methanol ingestion. These reported changes in central nervous system white and grey matter are sufficient to explain most of the various neurologic syndromes seen after methanol poisoning. These syndromes include parkinsonism, pseudobulbar palsy, cognitive defects with myelopathy, and frontal release signs. Martin-Amat et al and McMartin et al have shown that formate is the toxic agent responsible for the ocular damage, and formate is believed to be responsible for the non-ocular neurologic sequelae as well, although this has not yet been clearly established.

Which factors determine whether patients will present with neurologic symptoms and signs? In our patient group, patients with neurologic symptoms and signs on presentation had lower blood pH levels, and tended to have higher methanol levels. Sharp et al, in a study of 44 patients, showed that a low pH correlated with the presence of confusion and coma at presentation, but made no comment about the final outcome in these patients. They also showed that methanol levels tended to be higher in patients with severe neurologic signs and symptoms. In our study, those patients presenting with coma, seizures, or decreased visual acuity also tended to have a poor outcome.

The factors related to outcome and long term sequelae have been studied in more detail. Bennett et al found that if the plasma CO₂ was less than 20 mEq the mortality rate was 19%, but if the CO₂ was less than 10 mEq the mortality rate was 50%. However, others have reviewed the literature and found a trend but not a significant difference in the bicarbonate concentration in those patients with major sequelae (death and visual changes) versus those with no long term complications. Pappas and Silverman in a study of twelve patients found that the mean pH was lower in those patients that died. In our study, the pH was significantly lower in those patients with neurologic sequelae or death.

Methanol levels have been used as a criterion for aggressive treatment of methanol intoxication with hemodialysis, but have never been shown to correlate with outcome in terms of mortality or visual sequelae. There was no correlation between methanol levels and outcome in our study. This is likely because it is not the methanol but the conversion to formate that is responsible for the metabolic acidosis and structural damage to the central nervous system. In view of this, it is not surprising that a delay in treatment has an adverse affect on outcome. Gonda et al concluded that the interval from ingestion to treatment was important in determining outcome in his nine patients. Our present study also demonstrated that the interval from ingestion to treatment is important. Patients who could be treated promptly did significantly better than those in whom treatment was delayed. Fifty percent of our patients developed neurologic sequelae or death, and this poor outcome appeared to be related to a low pH at presentation and a delay in the initiation of treatment. Methanol levels did not correlate with outcome. Thus, it must be stressed that methanol levels should not be used as the sole criterion for aggressive treatment of methanol poisoning. Patients with a delay in presentation, especially if systemic acidosis has occurred are at significant risk for the development of long term neurologic sequelae. Early treatment remains the best way of avoiding serious neurologic complications and death in patients with methanol poisoning.

Table 3: Methanol Levels and pH at Presentation as Related to Outcome in 30 Patients with Methanol Poisoning

<table>
<thead>
<tr>
<th>Variable</th>
<th>Major Sequelae or Death (n = 15)</th>
<th>Survival with No Major Sequelae (n = 15)</th>
</tr>
</thead>
<tbody>
<tr>
<td>MEAN pH</td>
<td></td>
<td></td>
</tr>
<tr>
<td>+/-1 S.D. (range)</td>
<td>6.94 +/- 0.28 (6.46 - 7.42)</td>
<td>7.17 +/- 0.19 (6.67 - 7.35)</td>
</tr>
<tr>
<td>MEAN METHANOL +/-1 S.D. in mmol/L (range)</td>
<td>74.9 +/- 63 (5 - 315)</td>
<td>67.8 +/- 0.96 (1 - 84)</td>
</tr>
</tbody>
</table>

*p < 0.05
NS Not significant

Table 4: Time to Presentation Related to Outcome and Symptoms and Signs at Presentation in 30 Patients with Methanol Poisoning

<table>
<thead>
<tr>
<th>Time</th>
<th>Neurological Sequelae or Death (n = 15)</th>
<th>Survivors with No Sequelae (n = 15)</th>
<th>Neuro Manifestations at Presentation (n = 19)</th>
<th>No Neuro Manifestations at Presentation (n = 11)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Less than 8 hours</td>
<td>0</td>
<td>5 *</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>More than 8 hours</td>
<td>15</td>
<td>6</td>
<td>15</td>
<td>6</td>
</tr>
<tr>
<td>Unknown</td>
<td>0</td>
<td>4</td>
<td>2</td>
<td>2</td>
</tr>
</tbody>
</table>

*p < 0.05 for the No Sequelae group vs. the Neurological Sequelae or death group for less than 8 hours compared to greater than 8 hours.
REFERENCES


